JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
Drug Development
Samsung Biologics and LigaChem extend ADC services deal
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Korro secures approvals in Australia to commence AATD trial of KRRO-110
Arch Biopartners doses first subject in trial of acute kidney injury treatment
Disc Medicine secures $200m financing to support trials
OncoResponse reports data from Phase I solid tumour treatment trial
